Guidelines for Evaluation and Management of a Diffusely Heterogeneous Thyroid on Ultrasound

Diagnostic Workup

Measure serum TSH, free T4, and free T3 to determine thyroid functional status, and obtain anti‑TPO, anti‑thyroglobulin, and TSH‑receptor antibodies to identify autoimmune thyroid disease. 1
Order serum calcitonin when discrete thyroid nodules are identified, as it provides higher sensitivity than fine‑needle aspiration alone for detecting medullary thyroid carcinoma. 1

Assess cervical lymph nodes for suspicious features—size > 8–10 mm, loss of fatty hilum, microcalcifications, cystic change, or hypervascularity—to guide further investigation. 2

No routine imaging follow‑up is required for the diffuse heterogeneous appearance itself. 2
Initiate thyroid hormone replacement when serum TSH is elevated. 2
Perform surveillance ultrasound only for discrete nodules that meet size or suspicious‑feature criteria. 1

Color‑Doppler ultrasound can replace a radioiodine uptake scan to confirm Graves’ disease, demonstrating a sensitivity of ≈ 95 % and specificity of ≈ 90 %. 2
Treat hyperthyroidism with antithyroid medication, radioactive iodine, or surgery according to endocrinology guidelines. 2
Apply the same nodule surveillance criteria as for Hashimoto’s thyroiditis. 1

Nodules ≥ 1 cm: Perform ultrasound‑guided FNA when ≥ 2 suspicious sonographic features are present (marked hypoechogenicity, microcalcifications, irregular/microlobulated margins, absent peripheral halo, or central hypervascularity). 1
Nodules > 4 cm: Perform FNA regardless of sonographic appearance because of an increased false‑negative rate. 1
Suspicious cervical lymphadenopathy: Perform FNA of the associated thyroid nodule irrespective of size. 1
Nodules < 1 cm: Perform FNA only if suspicious sonographic features coexist with high‑risk clinical factors (history of head/neck irradiation, family history of thyroid cancer, age < 15 years, male gender, or subcapsular location). 1
If criteria are not met for nodules < 1 cm: Recommend surveillance ultrasound at 12–24 months to avoid overdiagnosis of clinically insignificant papillary microcarcinomas. 1

Do not perform FNA on ill‑defined hypoechoic areas that likely represent focal inflammation rather than true discrete nodules. 3
Repeat ultrasound in 4–6 months to determine whether the area persists as a measurable lesion. 3

Thyroid cancer occurs in ≈ 5–15 % of nodules and frequently coexists with autoimmune thyroid disease; therefore, discrete nodules must be evaluated with standard FNA criteria. 1
Thyroid function tests are unreliable for malignancy risk assessment because most thyroid cancers present with normal thyroid function. 1
A benign FNA result should not be overridden solely on the basis of persistent worrisome ultrasound features, as false‑negative rates can reach 11–33 % in heterogeneous glands. 1

Overdiagnosis accounts for approximately 77 % of thyroid cancer cases in the United States, underscoring the importance of applying size thresholds (e.g., ≥1 cm) before recommending fine‑needle aspiration to avoid unnecessary procedures and overtreatment. 4, 5